Amgen Inc. ($AMGN) Stock Forecast: Up 6.6% Today

What is Amgen Inc.?

Amgen (NASDAQ: AMGN) Market In the biotechnology sector, Amgen is recognized for its innovative therapies across different disease areas. Biotech stocks, including Amgen, have been attracting investor interest amid recent positive market sentiments and ongoing monitoring of financial results and regulatory updates.

Why is Amgen Inc. going up?

AMGN stock is up 6.6% on Feb 5, 2025 20:43

• During Q4, Amgen surpassed revenue and EPS expectations, impressing investors and boosting confidence in the company's growth trajectory.
• While facing a regulatory setback with the FDA's clinical hold on AMG 513 for obesity, Amgen's robust earnings performance outweighed concerns in the market.
• Favorable sentiment from influential investors and optimistic projections from analysts have contributed to Amgen's upward momentum.
• Despite regulatory hurdles, Amgen's financial strength and positive market outlook likely fueled today's significant bullish movement in the stock.

AMGN Price Chart

AMGN Technical Analysis

AMGN News

Amgen Impresses With Q4 Earnings Beat, Analysts See Growth Ahead - Amgen ( NASDAQ:AMGN )

Amgen's Q4 revenue grew 11% to $9.1 billion, beating estimates of $8.9 billion. Adjusted EPS of $5.31 topped consensus of $5.08, driven by strong sales. NOW OPEN: 200 Charter Memberships to Benzinga Trade Alerts

https://www.benzinga.com/25/02/43502578/amgen-impresses-with-q4-earnings-beat-analysts-see-growth-ahead

AMGN's Q4 Earnings Beat, Obesity Candidate Under FDA Clinical Hold

AMGN beats fourth-quarter estimates for earnings and sales. FDA places clinical hold on a phase I study on its obesity candidate, AMG 513.

https://www.zacks.com/stock/news/2410259/amgns-q4-earnings-beat-obesity-candidate-under-fda-clinical-hold

Amgen Options Trading: A Deep Dive into Market Sentiment - Amgen ( NASDAQ:AMGN )

High-rolling investors have positioned themselves bullish on Amgen AMGN, and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tracking of publicly available options data.

https://www.benzinga.com/insights/options/25/02/43498645/amgen-options-trading-a-deep-dive-into-market-sentiment

Are These 5 Biotech Stocks Set to Beat Q4 Earnings Estimates?

Let us look at some biotech stocks, AMGN, CRSP, MRNA, SRPT and VRTX, which are poised to beat on fourth-quarter earnings.

https://www.zacks.com/stock/news/2408061/are-these-5-biotech-stocks-set-to-beat-q4-earnings-estimates

Curious about Amgen ( AMGN ) Q4 Performance? Explore Wall Street Estimates for Key Metrics

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Amgen (AMGN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2024.

https://www.zacks.com/stock/news/2407475/curious-about-amgen-amgn-q4-performance-explore-wall-street-estimates-for-key-metrics

Trending Today

Sonic (prev. FTM) ($S) Crypto Forecast: Up 8.0% Today

Injective ($INJ) Crypto Forecast: Up 5.8% Today

Memecoin ($MEME) Crypto Forecast: Down 6.1% Today

Pepe ($PEPE) Crypto Forecast: Down 5.0% Today

Maker ($MKR) Crypto Forecast: Up 5.1% Today

Golem ($GLM) Crypto Forecast: Up 31.6% Today

Optimism ($OP) Crypto Forecast: Up 5.6% Today

MANTRA ($OM) Crypto Forecast: Up 10.9% Today

NEAR Protocol ($NEAR) Crypto Forecast: Down 5.1% Today

Ethereum ($ETH) Crypto Forecast: Up 5.1% Today

Amgen Inc. Price History

15.10.2024 - AMGN Stock was down 5.2%

• Concerns over the impact of Amgen's experimental weight loss injection, MariTide, on bone density appeared to have a notable effect on investor sentiment.
• Despite a surge in options trading and optimistic sentiments from well-funded investors, the safety concerns linked to MariTide outweighed the positive market sentiment.
• Comments from Jim Cramer on the stock's performance and potential advantages for competitor Eli Lilly notably contributed to the downward pressure on Amgen's shares.
• Overall, the market's response to the safety concerns surrounding MariTide eclipsed any positive developments, resulting in the decline of Amgen's stock price.

20.11.2024 - AMGN Stock was up 5.4%

• Despite a slight decrease in the most recent trading session, the overall bullish movement of Amgen's stock indicates strong investor confidence in the company.
• The -0.21% shift may be attributed to minor profit-taking or market fluctuations rather than any significant negative news impacting the company.
• Investors continue to show interest in Amgen due to its robust pipeline of biopharmaceutical products and potential for future growth in the healthcare industry.
• The positive sentiment towards Amgen aligns with the broader market optimism towards biotech companies, driving the stock's bullish movement.

05.01.2025 - AMGN Stock was up 5.4%

• The strong bullish movement of Amgen (AMGN) today is attributed to an impressive Q4 earnings report that surpassed expectations in both earnings and sales, indicating the company's strong financial position and growth potential.
• Despite the FDA's decision to place a clinical hold on Amgen's obesity candidate, AMG 513, which initially raised concerns among investors, the overall positive earnings results overshadowed this development.
• The high bullish sentiment among investors, evident from options trading data, further boosted the stock's upward trend, reflecting a positive outlook on Amgen's future.
• Despite the regulatory setback with AMG 513, Amgen's robust performance in Q4 and the optimistic market sentiment suggest that the company is well-positioned for continued growth within the biotech sector.

05.01.2025 - AMGN Stock was up 6.6%

• During Q4, Amgen surpassed revenue and EPS expectations, impressing investors and boosting confidence in the company's growth trajectory.
• While facing a regulatory setback with the FDA's clinical hold on AMG 513 for obesity, Amgen's robust earnings performance outweighed concerns in the market.
• Favorable sentiment from influential investors and optimistic projections from analysts have contributed to Amgen's upward momentum.
• Despite regulatory hurdles, Amgen's financial strength and positive market outlook likely fueled today's significant bullish movement in the stock.

26.10.2024 - AMGN Stock was down 11.9%

• The release of data from the Phase 2 study of MariTide showing weight loss of up to 20% in obese patients might have raised concerns about the drug's market potential, leading to a bearish sentiment.
• Despite the bullish options activity on Amgen, the overall market reaction to the obesity drug data seems to have overshadowed this positive sentiment.
• The bearish movement could also be influenced by investor uncertainty surrounding the competitive profile of other companies in the biopharmaceutical sector, as seen with Silence Therapeutics' stock decline despite positive study results.

05.01.2025 - AMGN Stock was up 5.1%

• Amgen (AMGN) experienced a strong bullish movement.
• The positive sentiment may stem from expectations of surpassing Q4 earnings estimates.
• Investors are optimistic about Amgen's performance for the quarter ending December 2024, contributing to the bullish trend.
• The market movement indicates faith in Amgen's potential to deliver robust financial outcomes, sparking investor enthusiasm for the stock.

13.10.2024 - AMGN Stock was down 5.0%

• Amgen's stock saw a decrease of over 7% due to findings of bone density loss in early trials of its experimental obesity drug MariTide. Investors are worried about the drug's potential risks and its impact on the company's future revenue.
• There are speculations that the recent news could advantage competitor Eli Lilly And Co (NYSE: LLY) as investors may turn their attention towards companies with more promising drug pipelines.
• Contrarily, Amgen and AstraZeneca Plc (NASDAQ: AZN) unveiled positive data from the Phase 3 WAYPOINT trial of Tezspire for patients with chronic rhinosinusitis with nasal polyps, representing a potential success in other areas of the company's drug portfolio.

25.08.2024 - AMGN Stock was down 5.2%

• Amgen's stock had a bearish movement today, possibly influenced by the competitive concerns raised by the data from the Phase 3 trials of rocatinlimab for atopic dermatitis.
• The denial of Regeneron Pharmaceuticals' effort to prevent the sale of Amgen's Eylea biosimilar might have added pressure on Amgen's stock, impacting investor sentiment.
• The bullish stance taken by investors with significant capital on Amgen's options could indicate a positive outlook for the company in the long term, despite the current bearish trend.
• Overall, the market reaction to recent developments and the competitive landscape in the biopharmaceutical sector likely contributed to Amgen's stock decline today.

25.08.2024 - AMGN Stock was down 5.2%

• Positive Phase 3 trial results of rocatinlimab in atopic dermatitis by Amgen were overshadowed by concerns from analysts regarding market competition, impacting investor sentiment negatively.
• A federal judge's decision to reject Regeneron Pharmaceuticals' attempt to block the sale of Amgen's Eylea biosimilar potentially hints at future competition for Amgen, contributing to the bearish movement.
• Investors with significant funds showed confidence in Amgen's long-term potential through a bullish approach on the company's options, despite the day's market decline.
• The convergence of encouraging trial findings, competitive apprehensions, and legal outcomes likely triggered the bearish trend observed in Amgen's stock today.

12.10.2024 - AMGN Stock was down 5.6%

• The bearish movement in Amgen's stock today could be attributed to the positive late-stage study results of AstraZeneca and Amgen's asthma drug, Tezspire, which may have underwhelmed investors' expectations for Amgen's own pipeline.
• The strong performance of Tezspire in the Phase 3 trial for chronic rhinosinusitis with nasal polyps might have raised concerns among investors about potential competition for Amgen's existing or future respiratory disease treatments.
• Investors may be reacting to the news by selling off Amgen's stock in the short term, anticipating potential challenges or shifts in market dynamics within the respiratory disease treatment space.

07.07.2024 - AMGN Stock was down 7.4%

• Amgen disclosed a mix of results in the second quarter, with earnings coming in below the expectations of analysts, resulting in a bearish market response.
• Analysts are placing emphasis on the imminent clinical updates in the areas of obesity and inflammatory disease, underscoring the pivotal role of forthcoming advancements for the company's expansion prospects.
• Despite exceeding the second-quarter predictions for earnings and sales, the stock witnessed a decline, suggesting that investors possibly sought more robust guidance or performance criteria.
• The prevailing market sentiment towards Amgen appears to be cautious due to immediate hurdles, yet analysts retain a positive outlook on the company's long-term growth possibilities.

08.07.2024 - AMGN Stock was up 5.1%

• Despite a revised guidance announcement, Amgen experienced a strong bullish trend in stock performance today, demonstrating resilience within the market.
• Investor negativity toward Amgen's options trading did not significantly impact the overall positive market sentiment toward the company.
• The second-quarter results, which displayed a mix of outcomes, brought attention to the potential of Amgen's obesity medication, potentially contributing to the stock's bullish movement.
• Eli Lilly's stock upsurge, driven by surpassing analyst expectations and raising guidance in the diabetes drug sector, likely had a favorable impact on the sentiment toward biotech firms like Amgen, contributing to the bullish trend.